Interferon-γ: teammate or opponent in the tumour microenvironment?
- 21 June 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 22 (3), 158-172
- https://doi.org/10.1038/s41577-021-00566-3
Abstract
Cancer immunotherapy offers substantive benefit to patients with various tumour types, in some cases leading to complete tumour clearance. However, many patients do not respond to immunotherapy, galvanizing the field to define the mechanisms of pre-existing and acquired resistance. Interferon-γ (IFNγ) is a cytokine that has both protumour and antitumour activities, suggesting that it may serve as a nexus for responsiveness to immunotherapy. Many cancer immunotherapies and chemotherapies induce IFNγ production by various cell types, including activated T cells and natural killer cells. Patients resistant to these therapies commonly have molecular aberrations in the IFNγ signalling pathway or express resistance molecules driven by IFNγ. Given that all nucleated cells can respond to IFNγ, the functional consequences of IFNγ production need to be carefully dissected on a cell-by-cell basis. Here, we review the cells that produce IFNγ and the different effects of IFNγ in the tumour microenvironment, highlighting the pleiotropic nature of this multifunctional and abundant cytokine.Keywords
This publication has 203 references indexed in Scilit:
- The NeST Long ncRNA Controls Microbial Susceptibility and Epigenetic Activation of the Interferon-γ LocusCell, 2013
- MicroRNA-29 Regulates T-Box Transcription Factors and Interferon-γ Production in Helper T CellsImmunity, 2011
- Inflammation driven by tumour-specific Th1 cells protects against B-cell cancerNature Communications, 2011
- T-bet represses TH17 differentiation by preventing Runx1-mediated activation of the gene encoding RORγtNature Immunology, 2010
- The role of tumour-derived iNOS in tumour progression and angiogenesisBritish Journal of Cancer, 2010
- Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell LymphomasMolecular Therapy, 2010
- The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammationNature Immunology, 2009
- An Essential Role of the Forkhead-Box Transcription Factor Foxo1 in Control of T Cell Homeostasis and ToleranceImmunity, 2009
- How regulatory T cells workNature Reviews Immunology, 2008
- Mechanism of CD1d-restricted natural killer T cell activation during microbial infectionNature Immunology, 2003